File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B

TitleResponse to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B
Authors
KeywordsHepatitis B
Lamivudine resistance
Renal allograft recipient
Issue Date2010
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CTR
Citation
Clinical Transplantation, 2010, v. 24 n. 2, p. 207-212 How to Cite?
AbstractWe studied the effects of adefovir or entecavir in six kidney transplant recipients (mean age 45.7 ± 7.8 yr) who developed hepatitic flare due to lamivudine-resistant hepatitis B virus (HBV) infection, with 18 months of follow-up. All patients had elevated alanine aminotransferase (ALT) levels and HBV DNA >105 copies/mL (median 2.15 × 108 copies/mL) at baseline. Serum creatinine and creatinine clearance levels were 137.8 ± 59.7 μmol/L and 62.6 ± 18.7 mL/min, respectively. Four patients were treated with adefovir and two with entecavir. Median HBV DNA decreased to 1.99 × 105 copies/mL (p = 0.028) after six months, 1.5 × 104 copies/mL (p = 0.043) after 12 months, and 7.35 × 104 copies/mL (p = 0.068) after 18 months of treatment. There was a corresponding improvement in ALT (34.5 ± 19.1 U/L after 18 months, p = 0.029 compared with baseline). The rate of HBV DNA suppression was variable, and three patients took over six months for the viral load to decrease to <105 copies/mL. After 18 months, HBV DNA was <105 copies/mL in four patients and <102 copies/mL in one patient. Treatment was well-tolerated and renal function remained stable. We conclude that both adefovir and entecavir are effective in the treatment of lamivudine-resistant HBV in renal allograft recpients, and the reduction of HBV DNA to <105 copies/mL could be slow. © 2009 John Wiley & Sons A/S.
Persistent Identifierhttp://hdl.handle.net/10722/129291
ISSN
2015 Impact Factor: 1.844
2015 SCImago Journal Rankings: 0.821
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTse, KCen_HK
dc.contributor.authorYap, DYHen_HK
dc.contributor.authorTang, CSOen_HK
dc.contributor.authorYung, Sen_HK
dc.contributor.authorChan, TMen_HK
dc.date.accessioned2010-12-23T08:34:45Z-
dc.date.available2010-12-23T08:34:45Z-
dc.date.issued2010en_HK
dc.identifier.citationClinical Transplantation, 2010, v. 24 n. 2, p. 207-212en_HK
dc.identifier.issn0902-0063en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129291-
dc.description.abstractWe studied the effects of adefovir or entecavir in six kidney transplant recipients (mean age 45.7 ± 7.8 yr) who developed hepatitic flare due to lamivudine-resistant hepatitis B virus (HBV) infection, with 18 months of follow-up. All patients had elevated alanine aminotransferase (ALT) levels and HBV DNA >105 copies/mL (median 2.15 × 108 copies/mL) at baseline. Serum creatinine and creatinine clearance levels were 137.8 ± 59.7 μmol/L and 62.6 ± 18.7 mL/min, respectively. Four patients were treated with adefovir and two with entecavir. Median HBV DNA decreased to 1.99 × 105 copies/mL (p = 0.028) after six months, 1.5 × 104 copies/mL (p = 0.043) after 12 months, and 7.35 × 104 copies/mL (p = 0.068) after 18 months of treatment. There was a corresponding improvement in ALT (34.5 ± 19.1 U/L after 18 months, p = 0.029 compared with baseline). The rate of HBV DNA suppression was variable, and three patients took over six months for the viral load to decrease to <105 copies/mL. After 18 months, HBV DNA was <105 copies/mL in four patients and <102 copies/mL in one patient. Treatment was well-tolerated and renal function remained stable. We conclude that both adefovir and entecavir are effective in the treatment of lamivudine-resistant HBV in renal allograft recpients, and the reduction of HBV DNA to <105 copies/mL could be slow. © 2009 John Wiley & Sons A/S.en_HK
dc.languageengen_US
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CTRen_HK
dc.relation.ispartofClinical Transplantationen_HK
dc.subjectHepatitis Ben_HK
dc.subjectLamivudine resistanceen_HK
dc.subjectRenal allograft recipienten_HK
dc.subject.meshAdenine - analogs & derivatives - pharmacology - therapeutic useen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshCreatinine - metabolismen_HK
dc.subject.meshDNA, Viral - analysisen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDrug Resistance, Viralen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGuanine - analogs & derivatives - pharmacology - therapeutic useen_HK
dc.subject.meshHepatitis B - complications - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney - drug effectsen_HK
dc.subject.meshKidney Transplantationen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPhosphonic Acids - pharmacology - therapeutic useen_HK
dc.subject.meshViral Load - drug effectsen_HK
dc.titleResponse to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.emailYap, DYH:desmondy@hku.hken_HK
dc.identifier.emailYung, S:ssyyung@hku.hken_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.authorityYap, DYH=rp01607en_HK
dc.identifier.authorityYung, S=rp00455en_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1399-0012.2009.01090.xen_HK
dc.identifier.pmid19758269en_HK
dc.identifier.scopuseid_2-s2.0-77952905778en_HK
dc.identifier.hkuros178488en_US
dc.identifier.hkuros210063-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77952905778&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue2en_HK
dc.identifier.spage207en_HK
dc.identifier.epage212en_HK
dc.identifier.isiWOS:000276356600014-
dc.publisher.placeDenmarken_HK
dc.identifier.scopusauthoridTse, KC=7102609864en_HK
dc.identifier.scopusauthoridYap, DYH=25958532000en_HK
dc.identifier.scopusauthoridTang, CSO=8681865300en_HK
dc.identifier.scopusauthoridYung, S=22636568800en_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.citeulike7066700-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats